Amelanotic Melanoma: Lower Survival Rates
Patients with amelanotic melanoma, a less pigmented form of skin cancer, face lower survival rates, according to a recent analysis. Men and older adults face a higher risk, highlighting the critical need for early detection and proactive treatment strategies for this primary_keyword. The study, spanning from 2000-2021, reveals insights into this challenging secondary_keyword, which frequently enough presents at a more advanced stage. The five-year disease-specific survival for amelanotic melanoma is alarmingly lower. However, thereS a glimmer of hope: Outcomes improved after 2011, possibly due to immunotherapy. News Directory 3 is committed to informing readers on the latest medical advancements. Discover what’s next in the fight against skin cancer.
Amelanotic Melanoma Patients Face Lower Survival Rates
Updated June 24, 2025
A recent analysis of the SEER database reveals that patients diagnosed with amelanotic melanoma, a less pigmented form of skin cancer, experience significantly lower disease-specific survival (DSS) compared to those with melanotic melanoma. The study,spanning from 2000 to 2021,examined nearly 1,600 cases of amelanotic melanoma and over 417,000 cases of melanotic melanoma.
The research indicated that individuals with amelanotic melanoma often present with more advanced stages of the disease. specifically, they are more likely to have regional or distant stage melanoma (26.8% vs. 12.4%), ulceration (35.6% vs. 13.1%), and a Breslow thickness greater than 2 mm (42% vs. 17%) at the time of diagnosis.
The five-year DSS for amelanotic melanoma was 78.6%, markedly lower than the 91.3% observed for melanotic melanoma. After adjusting for factors such as sex, age, and stage, patients with amelanotic melanoma still faced a 31% higher risk of mortality.
Further analysis showed that men with amelanotic melanoma had a 38% higher disease-specific mortality rate compared to women. Adults aged 85 and older also experienced higher mortality compared to those aged 45-64.
Interestingly,the study found that diagnoses of amelanotic melanoma made from 2011 onward were associated with a lower mortality risk. The two-year DSS for distant metastases more than doubled, increasing from 26.4% during 2000-2005 to 58.8% during 2016-2021. This improvement may be linked to the increased availability and use of immunotherapy.
“This study underscores the poorer survival outcomes associated with AM [amelanotic melanoma] compared to MM [melanotic melanoma] and highlights a potential survival improvement following the availability of immunotherapy,” the study authors wrote.
The study, led by Dr. Trang M. Nguyen of the National Hospital of dermatology and Venereology in Hanoi, Vietnam, appeared in the Journal of the American Academy of Dermatology. Researchers noted limitations including potential selection bias and limited follow-up data for recent cases. The authors declared no conflicts of interest or funding sources.
What’s next
The authors advocate for prospective trials to confirm these findings and to develop tailored management strategies for patients with amelanotic melanoma, potentially leveraging advancements in immunotherapy and targeted treatments.